Out of stock
Safety Advices
বাংলা
English
SAFE IF PRESCRIBED
Cephracap DS is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
SAFE IF PRESCRIBED
Cephracap DS is safe to use during breastfeeding. Human studies suggest that the drug does not pass into the breastmilk in a significant amount and is not harmful to the baby.
There may be a possibility of diarrhea or rash in the baby.
Medicine Overview of Cephracap DS 150mg Capsule
Introduction
Cephracap DS is an antibiotic that fights bacteria. It is used to treat acne, which appears as spots or pimples on your face, chest or back. This medicine works by attacking the bacteria that cause these pimples. Cephracap DS is only meant for external use and should be used as advised by your doctor. You should normally wash and dry the affected area before applying a thin layer of the medicine. It should not be applied to broken or damaged skin. Avoid any contact with your eyes, nose or mouth. Rinse it off with water if you accidentally get it...
... Show moreUses of Cephracap DS
Side effects of Cephracap DS
Common
- Skin rash
How to use Cephracap DS
This medicine is for external use only. Use it in the dose and duration as advised by your doctor. Check the label for directions before use. Clean and dry the affected area and apply the gel. Wash your hands after applying, unless hands are the affected area.
How Cephracap DS works
Cephracap DS is an antibiotic. It works by preventing synthesis of essential proteins required by bacteria to carry out vital functions. Thus, it stops the bacteria from growing, and prevents the infection from spreading.
What if you forget to take Cephracap DS?
If you miss a dose of Cephracap DS, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
Quick Tips
- You have been prescribed Cephracap DS for the treatment of acne.
- You may have to use it for a long time before your acne starts to improve. Be patient and keep using it every day.
- Wash your skin with a mild cleanser and pat it dry before applying Cephracap DS.
- Apply it as a thin layer onto clean, dry, unbroken skin affected by acne.
- It may cause minor burning, stinging or irritation when applied. Inform your doctor if this does not go away.
- Avoid contact with your eyes, nose or mouth. Rinse it off with water if you accidentally get the cream in these areas.
- If you think the area of skin you are treating has become more irritated and infected, you should stop using Cephracap DS and consult your doctor.
Brief Description
Indication
Dental infections, Respiratory tract infections, Skin and soft tissue infections, peritonitis, acne, anaerobic infections, endocarditis, Toxic shock syndrome, Bacterial vaginosis, Pelvic inflammatory disease
Administration
Cap: May be taken with or without food. Swallow whole w/ a full glass of water & in an upright position. Granules: Should be taken with food. IV Preparation Dilute 300 and 600 mg in 50 mL of D5W Dilute 900 mg in 50-100 mL of D5W Dilute 1200 mg in 100 mL of D5W IV Administration Intermittent IV infusion Infuse over 10-60 min at a rate not exceeding 30 mg/min 300 mg doses infuse over 10 min 600 mg doses infuse over 20 min 900 mg doses infuse over 30 min 1200 mg doses infuse over 60 min; no...
... Show moreAdult Dose
Adult: PO Serious anaerobic infections 150-300 mg 6 hrly, up to 450 mg 6 hrly for severe infections.
Max: 1.8 g/day.
Prophylaxis of endocarditis 600 mg 1 hr before dental procedure.
IV Serious anaerobic infections 0.6-2.7 g/day in divided does, up to 4.8 g/day for severe infections.
Toxic shock syndrome W/ penicillin G or ceftriaxone: 900 mg 8 hrly.
Pelvic inflammatory disease W/ gentamicin: 900 mg 8 hrly.
Bacterial Vaginosis: 300 mg PO q12hr for 7 days
Child Dose
Neonates (less than 1 month): 15 to 20 mg/kg/day in 3 to 4 equal doses. The lower effective dosage may be adequate for small prematures.
Child: PO 10–25 mg/kg/day q8h
30–40 mg/kg/day for CA-MRSA, intra-abdominal infection, or AOM
Parenteral (IV/IM) administration: 20–40 mg/kg/day q8h. The higher doses would be used for more severe infections.
Contraindication
Hypersensitivity.
Mode of Action
Clindamycin inhibits protein synthesis by reversibly binding to the 50S subunit of the ribosomal thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting to stunted cell growth.
Precaution
Renal and hepatic diseases; pregnancy and lactation; GI disease; elderly, females, neonates, atopic patients. Regular monitoring of blood counts, liver and kidney functions.
Lactation: Excreted in breast milk; manufacturer suggests discontinue drug or do not nurse (AAP Committee states compatible with nursing)
Side Effect
Diarrhoea, nausea, vomiting, abdominal pain; erythema multiforme, contact dermatitis, exfoliative and vesiculous dermatitis, urticaria; eosinophilia; local irritation, thrombophloebitis.
Potentially Fatal: Gasping syndrome (neonates); pseudomembranous colitis.
Pregnancy Category Note
Pregnancy In clinical trials with pregnant women, systemic administration of clindamycin during the second and third trimesters, has not been associated with increased frequency of congenital abnormalities Clindamycin should be used during first trimester of pregnancy only if clearly needed; there are no adequate and well-controlled studies in pregnant women during first trimester of pregnancy. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed Lactation Clindamycin has been reported to appear in breast milk in range of 0.5 to 3.8 mcg/mL; clindamycin has potential to cause...
... Show moreInteraction
May enhance the action of neuromuscular blocking agents (e.g. atracurium). May antagonise the effects of parasympathomimetics. May competitively inhibit the effects of macrolides, ketolides, streptogramins, linezolid and chloramphenicol. Increased coagulation tests (prothrombin time/INR) and/or bleeding w/ vit K antagonists (e.g. warfarin, acenocoumarol, fluindione).
